Johnson & Johnson (JNJ)

These companies haven't said their last words.

Even in a recession, there's strong demand for J&J's myriad of pharmaceutical and healthcare products.

For those waiting for a Nike turnaround, it looks like there's more waiting ahead.

Rising interest rates are unlikely to change the dynamics in the healthcare sector, where people are willing to pay for care.

These stocks should hold up well no matter what the future holds for the overall market.

VHT, BND, and VOO could be your best bets in the next economic downturn.

JNJ trades at a 28% discount on valuation while LLY's cardiometabolic drugs drive 82% of revenue, each bet carries distinct growth and concentration risks.

Johnson & Johnson's revenue base runs roughly double Bristol-Myers Squibb's, with the gap showing signs of widening over the past two years.

Jabil posted a double-beat quarter with nearly 29% revenue growth and 34% EPS growth, driven by AI demand, while maintaining buybacks and a Buy-rated analyst consensus.

Medtronic is following a strategy that has worked well for Johnson & Johnson.

Analysts think this beaten-down healthcare stock will rebound.

New investors might be eager to jump in during a bull market.

This is not an exhaustive list.

AbbVie, Johnson & Johnson and Merck offer growing dividends alongside healthcare pipeline catalysts, regulatory approvals and rising analyst price targets heading into 2027.

SHCD is missing some of the healthiest dividend stocks.

AbbVie bets on pipeline diversification amid patent cliffs, while J&J's higher profitability masks litigation risks, a choice between growth ambition and defensive stability.